Ruairidh Edwards

Associate Director Clinical Science & Translational Medicine Avacta Therapeutics

Ruairidh Edwards joined Avacta in 2022 and works on translational medicine for the pre|CISION® peptide–drug conjugate platform technology. He leads biomarker strategy, clinical translation and proof-of-mechanism studies supporting Avacta’s clinical development programmes. Prior to Avacta, Ruairidh completed his PhD in Biochemistry and Molecular Biology at the University of Glasgow, where he investigated mitochondrial biology, before continuing this research as a Postdoctoral Fellow at the University of Miami studying mitochondrial function in health and disease.

Seminars

Monday 8th March 2027
Showcasing a Phase I Trial of FAP-Exd (AVA6103), a Fibroblast Activation Protein (FAP)-enabled pre|CISION® Peptide-drug Conjugate Delivering Sustained Tumour Microenvironment (TME) Release of Exatecan in Patients with FAP-positive Solid Tumours
11:30 am
  • Avacta’s pre|CISION® peptide-drug conjugates are designed to selectively release potent cytotoxic payloads within the tumour microenvironment through FAP-mediated linker cleavage, with the aim of maximising tumour exposure while minimising systemic toxicity
  • AVA6103 (FAP-activated exatecan; FAP-Exd), the latest pre|CISION® peptide-drug conjugate in the clinic, is advancing through Phase 1a dose escalation, with Phase 1b expansion anticipated to commence in 2027
  • Highlighting emerging data from the AVA6103 programme, providing insights into target engagement, mechanism of action and the potential of FAP-enabled tumour-selective drug delivery in several solid-tumour types
Ruairidh Edwards - Avacta Therapeutics